SARS-CoV-1

Severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1; or severe acute respiratory syndrome coronavirus, SARS-CoV) is a strain of coronavirus that causes severe acute respiratory syndrome (SARS), the respiratory illness responsible for the 2002–2004 SARS outbreak. It is an enveloped, positive-sense, single-stranded RNA virus that infects the epithelial cells within the lungs. The virus enters the host cell by binding to angiotensin-converting enzyme 2 (ACE2). It infects humans, bats, and palm civets.

On April 16, 2003, following the outbreak of SARS in Asia and secondary cases elsewhere in the world, the World Health Organization (WHO) issued a press release stating that the coronavirus identified by several laboratories was the official cause of SARS. The Centers for Disease Control and Prevention (CDC) in the United States and the National Microbiology Laboratory (NML) in Canada identified the SARS-CoV-1 genome in April 2003. Scientists at Erasmus University in Rotterdam, the Netherlands, demonstrated that the SARS coronavirus fulfilled Koch’s postulates, thereby confirming it as the causative agent. In the experiments, macaques infected with the virus developed the same symptoms as human SARS patients.

A virus very similar to SARS was discovered in late 2019. This virus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is the causative pathogen of COVID-19, the propagation of which started the COVID-19 pandemic.

Electron micrograph coronavirus and spike protein subunit, with ACE2 binding domain in magenta.

Virology

SARS-CoV-1 follows the replication strategy typical of the coronavirus subfamily. The primary human receptor of the virus is angiotensin-converting enzyme 2 (ACE2) and hemagglutinin (HE), first identified in 2003. SARS-CoV-1 is one of seven known coronaviruses to infect humans. Including, Middle East respiratory syndrome–related coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

SARS-COV-2

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

SARS-COV-2 s a strain of coronavirus that causes COVID-19 (coronavirus disease 2019), the respiratory illness responsible for the ongoing COVID-19 pandemic. The virus previously had a provisional name, 2019 novel coronavirus (2019-nCoV), and has also been called the human coronavirus 2019 (HCoV-19 or hCoV-19). First identified in the city of Wuhan, Hubei, China, the World Health Organization declared the outbreak a public health emergency of international concern on January 30, 2020, and a pandemic on March 11, 2020. SARS-CoV-2 is a positive-sense single-stranded RNA virus that is contagious in humans.

SARS-CoV-2 is a virus of the species severe acute respiratory syndrome–related coronavirus, related to the SARS-CoV-1 virus that caused the 2002–2004 SARS outbreak. Despite its close relation to SARS-CoV-1, its closest known relatives, with which it forms a sister group, are the derived SARS viruses BANAL-52 and RaTG13. Available evidence indicates that it is most likely of zoonotic origin and has close genetic similarity to bat coronaviruses, suggesting it emerged from a bat-borne virus. Research is ongoing as to whether SARS-CoV-2 came directly from bats or indirectly through any intermediate hosts.  The virus shows little genetic diversity, indicating that the spillover event introducing SARS-CoV-2 to humans is likely to have occurred in late 2019.

Epidemiological studies estimate that, in the December 2019–September 2020 period, each infection resulted in an average of 2.4–3.4 new infections when no members of the community are immune, and no preventive measures are taken. However, some subsequent variants have become more infectious. The virus primarily spreads between people through close contact and via aerosols and respiratory droplets that are exhaled when talking, breathing, or otherwise exhaling, as well as those produced from coughs and sneezes. It enters human cells by binding to angiotensin-converting enzyme 2 (ACE2), a membrane protein that regulates the renin–angiotensin system.

It is of note that this virus has never been isolated in any laboratory worldwide. Although many have claimed it has been isolated, on demand no laboratory or government has been able to supply any peer reviewed evidence of its isolation.

Replication cycle

Virus infections start when viral particles bind to host surface cellular receptors. Protein modelling experiments on the spike protein of the virus soon suggested that SARS-CoV-2 has sufficient affinity to the ACE2 receptor on human cells to use them as a mechanism of cell entry. By 22 January 2020, a group in China working with the full virus genome and a group in the United States using reverse genetics methods independently and experimentally demonstrated that ACE2 could act as the receptor for SARS-CoV-2. Studies have shown that SARS-CoV-2 has a higher affinity to human ACE2 than the original SARS virus.

Initial spike protein priming by transmembrane protease, serine 2 (TMPRSS2) is essential for entry of SARS-CoV-2. The host protein neuropilin1 (NRP1) may aid the virus in host cell entry using ACE2. After a SARS-CoV-2 virion attaches to a target cell, the cell’s TMPRSS2 cuts open the spike protein of the virus, exposing a fusion peptide in the S2 subunit, and the host receptor ACE2. After fusion, an endosome forms around the virion, separating it from the rest of the host cell. The virion escapes when the pH of the endosome drops or when cathepsin, a host cysteine protease, cleaves it. The virion then releases RNA into the cell and forces the cell to produce and disseminate copies of the virus, which infect more cells.

SARS-CoV-2 produces at least three virulence factors that promote shedding of new virions from host cells and inhibit immune response.

Digitally colourised scanning electron micrographs of SARS-CoV-2 virions (yellow) emerging from human cells cultured in a laboratory.

What if traditional medicine has got it all backwards?

Let us assume for a moment that the causative agent (SARS-COV-2) [the Virus] is the expressed result of an undisclosed injury to the nucleus of a cell. The damaged cell nucleus could then produce an unwanted mRNA string and via the Golgi apparatus, package the mRNA as an endosome into the cytoplasm of the cell. From here the endosome would extrude the unwanted mRNA into the circulation as exosomes. This exact process was the subject of the medical Nobel Prize in 2013.

The exosome package now binds with the ACE2 receptors of target cells, and the cells respond by producing copies of the mRNA strand and again expel many more unwanted mRNA strands within further exosomes, but now in a cascading fashion. The immune system responds with white blood cells trying to contain the problem RNA, and the result is the clinical picture we call COVID-19, or the immune system is overwhelmed, and AIDS occurs. If the target cell responds to the exosome payload with cellular differentiation, the result may be dysplastic and if uncontrolled, Cancer.

5G as a potential cause of exosomes

An Observational Study on the Effect of 5G in COVID-19 Confirmed Cases

Abstract

This observational study assesses public data on the distribution of active 5G technology and the relationship with COVID-19 confirmed cases on a global basis ex-China. The data set was current on the 4 April 2020 and analysis shows 96% of confirmed cases and 98% of deceased cases are from active 5G areas. The results imply exposure to 5G-EMR may influence mortality that has less than 1% chance of occurring by chance alone (p-Value 0.0057). However, the mortality rate in cases claimed to be COVID-19 (27%) is the same for known outcome cases (deceased and recovered cases), whether exposed to 5G or not and we might expect the rate to be higher in the 5G exposed group. Perhaps, 5G exposure is occurring where there are more people and hence more cases. Alternatively, exosomes seen by electron microscopy in known cases may be a response to cellular injury from EMR and not from viral loading. The background rate of deaths in non-5G areas may then be explained by 4G and other EMR exposure.

From a public health perspective, further assessment of the effects of high frequency EMR technology on human cells is required.

Introduction

There has been much speculation regarding the effects of 5G as a form of high frequency electromagnetic radiation (EMR) and whether the adoption of this technology has any effects on human cells. The study compares the outcomes of confirmed COVID-19 cases in areas where 5G is being tested and/or commercially available to those areas where 5G is yet to be adopted.

Methodology

Live global reporting of confirmed cases, deceased cases, recovered cases and serious cases was obtained from ncov2019.live. Active 5G technology was mapped by Ookla and each county were then cross referenced to articles online confirming active 5G rollout and/or active testing. The data was then divided geographically on a country-by-country basis. The full data set was divided into countries having active 5G technology and those countries without active 5G technology.

Ookla 5G Map

Figure 1 – Ookla 5G Map

Global Confirmed Cases

Confirmed cases were allocated by positive RT-PCR or on a clinical decision with chest radiograph or thoracic CT. After being allocated to the confirmed cases group, each case may be home managed or progress to be a serious case requiring hospital treatment. Thereafter, becoming deceased cases or recovered cases. On April 4, 2020 total cases are reported including China, in Figure 2.

Region	Confirmed	Deceased	Recovered	Serious
World	1,096,274	58,805	221,818	35,421
China	83,269	3,322	76,745	379

Confirmed Cases Ex China

200 countries and one vessel are reporting COVID-19 cases; excluding China, 84 countries and one reporting vessel have active 5G facilities; 115 countries have no active 5G. COVID-19 cases by country 5G status are shown in Figures 3 and 4.

5G Exposure	Confirmed	Serious	Deceased	Recovered
No	38,730	488	941	2,828
Yes	974,275	34,554	54,542	142,245
Total	1,013,005	35,042	55,483	145,073
Figure 3 – Confirmed cases Ex China 4 April 2020
5G Exposure	Confirmed	Serious	Deceased	Recovered
No	3.82%	0.05%	0.09%	0.28%
Yes	96.18%	3.41%	5.38%	14.04%
Total	100.00%	3.46%	5.48%	14.32%

Mortality Rates in Active 5G Areas

There is a substantial difference in the number of deceased cases in active 5G areas, with 98.30% of deceased cases occurring in areas with exposure to 5G-EMR. Refer Figure 5.

COVID-19 Cases	Deaths	%
No-5G	941	1.70%
5G	54,542	98.30%
Total	55,483	100.00%

T Test

P-Values are statistically significant when comparing each metric. The data suggests the probability of the results occurring by chance and not due to 5G exposure of COVID-19 cases is under 1% for active cases (confirmed and serious) and for known outcomes (resolved cases and deceased cases). Although, other reasons for rejecting the null hypothesis should be explored, it is unlikely to be due to chance alone.

P-Values	4 April 2020
Confirmed Cases	0.0030
Deceased Cases	0.0057
Serious Cases	0.0024
Recovered Cases	0.0028

Mortality Areas

The top ten countries for 5G and non-5G activity is presented in Figures 7 and 8.

5G Exposure	Confirmed	Serious	Deceased	Recovered
United States	274,178	7,053	10,821	5,176
Italy	119,827	14,681	19,758	4,068
Spain	119,199	11,198	26,743	6,092
Germany	91,159	1,275	30,230	2,424
France	64,338	6,507	9,444	6,662
Iran	53,183	3,294	17,935	4,035
United Kingdom	38,168	3,605	135	20
Turkey	20,921	425	484	1,251
Switzerland	19,702	604	5,657	0
Belgium	16,770	1,143	2,872	1,205
Total	817,445	49,785	124,079	30,933

No 5G Exposure	Confirmed	Serious	Deceased	Recovered
Israel	7,428	40	403	113
Chile	3,737	22	335	142
Luxembourg	2,612	31	174	33
India	2,590	72	188	0
Indonesia	1,986	181	134	0
Mexico	1,510	50	35	17
Serbia	1,476	39	0	49
Panama	1,475	37	10	69
Iceland	1,364	4	336	11
Colombia	1,267	25	55	0
Total	25,445	501	1,670	434

An argument could be made for case numbers presenting being higher in active 5G countries due to larger populations concentrated around active 5G facilities. On the other hand, it could also be argued that 5G would be installed in populous areas and high traffic transport hubs.

Mortality Rates for Known Outcomes

Known outcomes are deceased cases and recovered cases.

The mortality rate is the percentage of deceased cases per known outcome.

COVID-19 Cases	No-5G	5G		COVID-19 Cases	No-5G	5G
Deaths	447	30,151		Deaths	28.76%	27.41%
Recoveries	1,107	79,852		Recoveries	71.24%	72.59%
Known Outcomes	1,554	110,003		Known Outcomes	100.00%	100.00%

Mortality rates are similar for exposed and non-exposed 5G-EMR cases and more granular data could assess this further. If 5G-EMR were acting synergistically or in tandem with COVID-19 to increase its effects, then a higher mortality-rate would be expected in COVID-19 cases exposed to active 5G-EMR, and not just a higher case-rate. The data confirms that EMR is the cause and logically must be the only cause (not acting synergistically or in tandem). In addition, the lower case-rate with similar mortality-rates in non-5G areas, must be due to the same pathological process occurring less frequently. This is explained in non-5G areas where cases are exposed to lower frequency 3G or 4G-EMR. In these non-5G areas, less subjects would meet the criteria for EMR related mortality because of less aggressive (lower frequency) EMR exposure. Due to the nature of the effects of exposure to EMR, it will not be possible to conduct randomised controlled clinical trials. Therefore, clinicians and public health officials should take action based on the best available observational data.

In other words, COVID-19 is observed effect of EMR exposure, not a virus.

Diagnostic Tests

COVID-19 is a clinical diagnosis that does not require but can be confirmed with diagnostic testing (true positives). Whereas positive diagnostic tests in the absence of a clinical diagnosis may reflect false positive cases (over sensitive) or (non-specific) tests, which overestimate true disease rates.

RT-PCR (reverse transcription Polymerase Chain Reaction) tests are deemed to detect the presence of coronavirus. The RT-PCR test is based on the detection of the virus genome from a nasopharyngeal sample. It enables the confirmation of whether the person (at the time of the test) is infected with the virus but is only relevant in cases accompanied by a clinical diagnosis of the condition.

Serological testing looks for antibodies of IgM and IgG classes specific to SARS-CoV-2 by means of a blood sample. Serology enables the definition of the immune status of a person, in clear terms of whether they are immune to the virus, even if they have no symptoms. Immune cases do not require vaccination and serology can be used as a screening process to determine whether a vaccination is relevant, or if the person is naturally immune. SARS-COV-2 seropositivity maybe the natural antibody produced in response to 5G-EMR nuclear damage, wild SARS-COV-2 exposure, or COVID-19 vaccination.

To avoid false negatives, health professionals emphasize that it is necessary to explore both nostrils when sampling and in severe cases, a sampling in the trachea or bronchi may be more relevant since the virus gradually migrates to the respiratory tract. After a few days, the viral load in the nose of a patient with COVID-19 could be zero but in these clinical cases the serology would then most likely be positive. Oversampling leads to over diagnosis, and no sampling is required in the absence of clinical symptoms.

The RT-PCR test, although used for diagnostic purpose, is not intended to detect the presence of the specific virus genome of COVID-19 disease, but only ‘genetic material’ that may have more generalised and quite non-specific origins e.g., a previous cold or flu. Despite this, people tested and found positive by RT-PCR are diagnosed as being infected with COVID- 19 and subsequent morbidity and deaths are then attributed to COVID-19 disease, even if no clinical diagnosis were made. This is not correct clinical practise.

Furthermore, the amplification cycle used in the laboratory processing of RT_PCR samples varies in different countries and can make tests over-sensitive. This determines the number of false positive tests and therefore cases diagnosed. It is a technique that could be utilised to manufacture cases.

True cases would be clinically symptomatic, RT-PCR positive, and serologically positive for SARS-COV-2 and even then, the index clinical case may be due to 5G-EMR exposure, or the consequence of COVID-19 RNA-vaccination and not due to exposure to wild SARS-COV-2 virus (if it even exists).

Sources of Exosomes

Parasites and Solvents

Elsewhere, extensive documentation is presented confirming the presence of virus/exosomes in the serum of cancer patients carrying the fasciolopsis buski trematode parasite and exposed to isopropyl alcohol, and in HIV/AIDS patients carrying ascaris parasites and exposed to benzene.

COVID-19 Vaccines and Lipids

Many people are curious to know what the ingredients are for the two main COVID-19 vaccines in the western world. Here is a breakdown of these COVID vaccines and their ingredients:

• Pfizer/BioNTech – The full list of ingredients for the Pfizer vaccine is mRNA, lipids ((4-hydroxybutyl) azanediyl) bis (hexane-6,1-diyl) bis (2-hexyldecanoate), 2 [(polyethylene glycol)-2000]-N, N- ditetradecylacetamide, 1,2-Distearoyl-sn-glycero-3-phosphocholine, and cholesterol), potassium chloride, monobasic potassium phosphate, sodium chloride, dibasic sodium phosphate dihydrate, and sucrose.

• Moderna – The full list of ingredients for the Moderna vaccine is messenger ribonucleic acid (mRNA), lipids (SM-102, polyethylene glycol [PEG] 2000 dimyristoyl glycerol [DM], cholesterol, and 1,2-distearoyl-sn- glycero-3-phosphocholine [DSPC]), tromethamine, tromethamine hydrochloride, acetic acid, sodium acetate trihydrate, and sucrose.

Both contain mRNA and a lipid called PEG 2000. This lipid encapsulates the mRNA and helps to protect it on route to being absorbed into the cell. The spike protein is then manufactured and extruded as an exosome to bind target receptors (ACE2) on other cells and multiply further. The intention is to cause the immune system to produce antibodies to the spike protein, which in turn prevents future exposure to wild virus from starting a large-scale immunological assault.

Summary of Exosomes

Exosomes [RNA/DNA packages] are:

• Present in Parasites,
• Present in Bacteria within Parasites,
• Present in response to EMR cellular damage,
• Present in COVID-19 Vaccines, and

in the presence of certain solvents produce cancer, HIV and AIDS, Long-COVID, and Post Vaccination injuries.

Ivermectin

There is evidential data supporting the use of Ivermectin in the prevention and treatment of COVID-19. DARPA investigated the effectiveness of several potential compounds against SARS-COV-1 (2003 onwards) and later SARS-COV-2 (2020), concluding that Ivermectin, Hydroxychloroquine and Interferon were all curative by May 2020.

The best of these was Ivermectin [IVM] which showed the highest affinity for binding the ACE2 receptor, which implies it will be the least likely candidate to be displaced by active SARS-COV-2 spike protein. Consequently, the effects of the virus and the damaging immunological cascade beyond can both be prevented by Ivermectin.

Candidates with high ACE2 receptor binding include Ivermectin (antiparasitic) > Heparin > Azithromycin > Clarithromycin > Erythromycin > Niclosamide (antihelminth) > Ritonavir (anti-viral).

Based on plentiful reports we imagine that a successful treatment regime should contain multi drugs of protease inhibitors, spike shielding drugs, and immunomodulatory drugs in early steps of the disease. Ivermectin > heparin (as intravenous or nebulized) > macrolides (azithromycin, clarithromycin, erythromycin) seem to be good adjuvant candidates in all anti 2019-nCov regimes to shield S protein even for prophylactic purposes.

The Case for Ivermectin

The full review supporting IVM as the pre-emptive drug for the prevention and treatment of COVID-19 is detailed below from the Front Line COVID-19 Critical Care (FLACCC) Alliance. This information was comprehensively presented by the testimony of Pierre Kory, MD at the US Senate Homeland Security Committee Meeting: Focus on Early Treatment of COVID-19 on December 8, 2020.

For comprehensive information on ivermectin please refer to the Review of the Emerging Evidence Supporting the Use of Ivermectin in the Prophylaxis and Treatment of COVID-19 and the included references.

While ivermectin is a remarkably safe drug with minimal adverse reactions (almost all minor), some potential drug-drug interactions should be reviewed before prescribing ivermectin. The most important drug-drug interactions occur with cyclosporin, tacrolimus, antiretroviral drugs, and certain antifungal drugs.

IVM plays a central role in preventing and treating Cancer, HIV & AIDS, COVID and vaccine injury

There are two parasites that are responsible for causing the initial exosome RNA payload. One producing cancer and the other HIV. Cancer is uniquely linked to Fasciolopsis Buski, an intestinal trematode (fluke), which is responsive to Praziquantel treatment or potentially the Dr Clark natural treatment protocol. HIV and AIDS is uniquely linked to the Ascaris parasite, which is responsive to Ivermectin treatment or again potentially the Dr Clark natural treatment protocol. Ivermectin cannot be used to treat trematodes but will prevent AIDS and the immune acquired consequences of Vaccine Injury.

The Dr Clark natural parasite cleanse is very broad spectrum, potentially eradicating most if not all parasites from the body. This may be followed by maintenance therapy to prevent recurrence. A treatment protocol combining both approaches would logically seem the best overall approach, which must then be followed by a combination maintenance programme.

Lifestyle changes to minimize the presence of EMR, isopropyl alcohol, benzene, food mould, and a dental clean-up would be advisable, but is not required providing the maintenance regime is continued.

Other drug candidates include chloroquine (CQ), hydroxychloroquine (HCQ), azithromycin, zinc supplementation, LMW heparin, interferon, and ritonavir.

SARS-CoV-2 lifecycle and several inhibitory mechanisms of CQ/HCQ. The journey of antimalarial drugs against SARS-CoV-2: Review article, Amany A. Sarhan et al. Department of Pharmaceutical Medicinal Chemistry, Faculty of Pharmacy, Horus University-Egypt

The Protocol for treating and curing Cancer, HIV & AIDS, COVID, Post Vaccine injuries & Long COVID

About this protocol

The information in this document is our recommended approach to Cancer, HIV & AIDS, COVID-19, Long COVID and Post Vaccine Treatment.

It is provided as guidance to those persons suffering from the conditions, and their healthcare providers worldwide on the treatment of Cancer, HIV & AIDS, COVID-19, Long COVID and Post Vaccine Treatment.

Patients should always consult with their provider before starting any medical treatment.

New medications may be added and/or changes made to doses of existing medications as further evidence emerges. Please check our website to be sure you are using the latest version of this protocol.

Early treatment is critical and a most important factor in managing these diseases.

Please consult your medical service provider for information on the side effects of medications, common drug interactions, safety of use of vitamins and nutritional supplements, particularly in children and pregnancy.    

A Guide to the Treatment of Cancer, HIV & AIDS, COVID-19, Post Vaccine Treatment and Long COVID

COVID-19 is a clinical diagnosis; a confirmed antigen or PCR test is helpful but not required. Treatment should be initiated immediately after the onset of flu-like symptoms. Similar symptoms may be experienced after vaccination for COVID-19 with RNA based vaccines, and with Long-COVID. Cancer begins with the parasite Fasciolopsis Buski, in the presence of Isopropyl Alcohol. HIV & AIDS begin with the parasite Ascaris, in the presence of Benzene. Fasciolopsis Buski and Ascaris expel exosomes, which create similar symptoms and immunological consequences to COVID-19, COVID-19 vaccines, post vaccination states and Long-COVID. The base Protocol is identical for all treatment modalities, with Cancer requiring the addition of Praziquantel treatment. Given the increase in all-cause mortality post vaccine, including Cancer it may be prudent to add Praziquantel to all treatment protocols.

• Praziquantel: 75mg/Kg/day orally in three divided doses for 2 days. Refer Table 4 for dosing e.g., 70Kg => 5250mg => 600mg Tab, take three, three times a day. Take with liquids during a meal. May be combined with Dr Clark naturopathic Protocol for parasite cleanse (table 6). Refer table 1 for dosing. Repeat 3 monthly.
• Fenbendazole: 20 mg/Kg daily for 5 days. Take from day 3 after Praziquantel is finished. Refer table 2 for dosing.  Repeat 3 monthly.
• Ivermectin: 0.4 mg/kg – one dose daily for 5 to 10 days. Refer table 3 for dosing. Ivermectin is best taken with or after a meal, for greater absorption. Repeat 3 monthly.
• Oral antibiotic: Azithromycin (500 mg daily for 5 days). Repeat 3 monthly.
• Zinc: 75-100 mg daily, for 5 days. Repeat 3 monthly.
• Vitamin C: 500-1000 mg twice a day. Daily.
• Vitamin D3: See dosing in table 4. Check blood level 3 monthly, repeat as required.
• B complex vitamins: One Tab, each morning. Daily.
• Melatonin: 5-10 mg before bedtime (causes drowsiness). Slow- or extended-release formulations preferred. Or take Ornithine. Daily.
• N-acetyl cysteine (NAC): 600-1200 mg orally twice a day. Daily.
• Omega-3 6 9 fatty acids: 3 -4 g daily e.g.,1200 mg three times per day. Daily.
• Quercetin: 500 mg twice a day. Avoid in Hypothyroidism. Daily. Due to a possible interaction between quercetin and ivermectin, these drugs should not be taken simultaneously (e.g., take IVM in the morning and Quercetin in the evening).
• Curcumin (turmeric): 500 mg twice a day. Use for less than 14 days. Curcumin has low solubility in water and is poorly absorbed by the body; consequently, it is traditionally taken with full fat milk and black pepper, which enhance its absorption.
• Ornithine: 500 mg at bedtime: Or take Melatonin. Daily. Take Ornithine at night if insomnia occurs with removal of parasites.
• Arginine: 300 mg each morning: One each morning. Daily. Arginine in the morning for energy.
• Honey: 1 g/kg one to two times a day. Daily.

Optional:

• Mouthwash: 3 times a day. Gargle three times a day (do not swallow) with an antiseptic-antimicrobial mouthwash containing 1% povidone-iodine.
• Nasal spray with 1% povidone-iodine: 2-3 times a day. Do not use for more than 5 days in pregnancy.

Add to first line therapies above if: poor response to first line agents.

• Nitazoxanide: 500 mg twice or three times daily for 5 days. Taken with a fatty meal. If no improvement on Ivermectin, substitute Nitazoxanide.

The information in this document is our recommended approach to Cancer, HIV & AIDS, COVID-19, Long COVID and Post COVID Vaccine Treatment. It is provided as guidance to healthcare providers and individuals for the prevention and treatment of Cancer, HIV & AIDS, COVID-19, Long COVID and Post COVID Vaccine morbidities. Patients should always consult with their provider before starting any medical treatment. New medications may be added and/or changes made to doses of existing medications as further evidence emerges. Please check our website to be sure you are using the latest version of this protocol. Early treatment is critical and a most important factor in managing these diseases.

Reference Tables

Praziquantel Dose

Praziquantel tablets are available in different strengths of 100 – 600mg. Do not under dose. Tablets can be halved for more accurate dosing. Take three times per day no less than 4 hours and no more than 6 hours apart. Doses below are calculated for the upper end of the weight ranges listed.

Weight in Kg	Breakfast	Lunch	Dinner
32–40 kg	1,000 mg	1,000 mg	1,000 mg
41–50 kg	1,250 mg	1,250 mg	1,250 mg
51–60 kg	1,500 mg	1,500 mg	1,500 mg
61–70 kg	1,750 mg	1,750 mg	1,750 mg
71–80 kg	2,000 mg	2,000 mg	2,000 mg
81–90 kg	2,250 mg	2,250 mg	2,250 mg
91–100 kg	2,500 mg	2,500 mg	2,500 mg
101–110 kg	2,750 mg	2,750 mg	2,750 mg
111–120 kg	3,000 mg	3,000 mg	3,000 mg
121–130 kg	3,250 mg	3,250 mg	3,250 mg
131–140 kg	3,500 mg	3,500 mg	3,500 mg

Fenbendazole Dose

Do not under dose. Tablets can be halved for more accurate dosing. Take once per day with food in the morning. Doses below are calculated for the upper end of the weight ranges listed.

Weight in Kg	Fenbendazole Dose (mg)
32–40 kg	800 mg
41–50 kg	1,000 mg
51–60 kg	1,200 mg
61–70 kg	1,400 mg
71–80 kg	1,600 mg
81–90 kg	1,800 mg
91–100 kg	2,000 mg
101–110 kg	2,200 mg
111–120 kg	2,400 mg
121–130 kg	2,600 mg
131–140 kg	2,800 mg

Ivermectin dose

Ivermectin tablets are available in different strengths of 3, 6, or 12 mg. Do not under dose. Tablets can be halved for more accurate dosing. Doses below are calculated for the upper end of the weight ranges listed.

Weight in Kg	Dosage per day
32–40 kg	16mg
41–50 kg	20 mg
51–59 kg	24 mg
60–68 kg	27 mg
69–77 kg	30 mg
78–86 kg	32 mg
87–95 kg	36 mg
96–104 kg	40 mg
105–113 kg	44 mg
114–122 kg	48 mg
123–131 kg	52 mg
132–140 kg	56 mg

Single-Dose Regimen of Calcifediol to Rapidly Raise Serum 25(OH)D above 50 ng/ml.

Body Weight (Kg)	Calcifediol (mg)	Equivalent in IU	If Calcifediol is not available, a bolus of Vitamin D3
7–10	0.1	16,000	20,000
10–14	0.15	24,000	35,000
15–18	0.2	32,000	50,000
19–23	0.3	48,000	60,000
24–27	0.4	64,000	75,000
28–32	0.5	80,000	100,000
33–39	0.6	96,000	150,000
40–45	0.7	112,000	200,000
46–68	0.8	128,000	250,000
69–90	1	160,000	300,000
91–136	1.15	240,000	400,000
>137	2	320,000	500,000

Proposed Medication Plan for First Line Treatments

Item	Breakfast	Lunch	Dinner	Bedtime
Ivermectin		√
Praziquantel	√	√	√
Fenbendazole	√
Azithromycin	√
Zinc	√
Vitamin C	√		√
Vitamin D3/Calcifediol	√
B Complex Vitamins	√
N-Acetyl Cysteine (NAC)	√		√
Omega-3 Fatty Acids	√
Mouthwash/Nasal Spray	√	√	√
Quercetin	√		√
Curcumin (Turmeric)	√		√
Ornithine				√
Arginine	√

18 Day Parasite Cleanse Chart – Dr Hulda Clarke regime – For reference only.
	Green-Black Walnut Hull – Extra Strength Tincture		Wormwood Capsules	Clove Capsules
DAY	Number of drops once a day on an empty stomach, 15-45 min before a meal, in 1/2 a cup of water.		Number of capsules once a day on empty stomach, 15-45 min before a meal, or at mealtime, if you have a sensitive stomach.	Number of capsules 3 times a day on empty stomach, 15-45 min before a meal, or at mealtime, if you have a sensitive stomach.
1	1 drop		1	1,1,1
2	2 drops		1	2,2,2
3	3 drops		2	3,3,3
4	4 drops		2	3,3,3
5	5 drops		3	3,3,3
6	2 tsp. all at once		3	3,3,3
7	–		4	3,3,3
8	–		4	3,3,3
9	–		5	3,3,3
10	–		5	3,3,3
11	–		6	7 caps, all at once, weekly
12	–		6	–
13	2 tsp. all at once		7	–
14	–		7	–
15	–		7	–
16	–		7	–
17	–		7	–
18	–		7 caps. all at once, weekly	7 caps. all at once, weekly
Now pick a day to stay on your Maintenance.  Around days 23-25, this should start.
Maintenance Chart
The maintenance is simple.  Just take the max dose ONCE WEEKLY.  15-45 min before a meal, or at mealtime if you have a sensitive stomach.
Day	25	2 tsp. all at once	7 caps. all at once	7 caps. all at once
32		2 tsp. all at once	7 caps. all at once	7 caps. all at once
Continue weekly – For best overall health results stay on the Parasite Weekly Maintenance Program indefinitely (as suggested by Dr Clark) or for at least 3 months.

Disclaimer

The Cancer, HIV & AIDS, COVID-19, and post Vaccine Treatment Protocol is meant solely for educational purposes regarding potentially beneficial treatment approaches for these conditions. Never disregard professional medical advice because of something you have read on our website and releases. This is not intended to be a substitute for professional medical advice, diagnosis, or treatment regarding any patient. Treatment for an individual patient is determined by many factors and thus should rely on the judgement of your physician or qualified healthcare provider. Always seek their advice with any questions you may have regarding your medical condition or health. Use of any material content on the Website [sanogenix.com] assumes you have read and agreed to the published Terms and Conditions.

© Sanogenix 2023 | All rights reserved